Press Releases
// Jan 05, 2023
ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference
// Nov 15, 2022
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers
// Aug 25, 2022
ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation
// Aug 23, 2022
ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines
// Aug 04, 2022
ElevateBio Announces the Formation of a New Company with George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies
// Jun 02, 2022
ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development
// May 04, 2022
ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
// Jan 06, 2022
ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference
// Nov 15, 2021
ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform
// Oct 27, 2021
ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics
// Jun 29, 2021
